There were two trials involving BsAbs for lymphoma in China to date, with one focusing on anti-cytotoxic T lymphocyte associate protein-4 (CTLA-4) /PD-1 (NCT04444141) and one on anti-CTLA-4/PD-L1 (NCT03733951). Here, CD274 is linked to lymphoma.